This is a landmark day for peptides. I recorded this at 6 AM the morning between day one and day two of the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting, and I'm breaking down exactly what happened, why it matters, and what it means for you depending on where you live.
On day one, the committee voted YES on all four peptides they reviewed: BPC-157, TB-500, KPV, and MOTS-c. This went against the FDA scientists' own recommendation. There was an audible gasp in the room. Today they're voting on DSIP, Epitalon, and Semax, and I expect all three to pass too. If you'd like to work with me one-on-one, you can book a free call here.
Timestamps:
- 00:00 Welcome + why this is a landmark peptide moment
- 04:50 What the FDA PCAC panel voted on and why it shocked everyone
- 08:00 Peptides have a champion at the very top (RFK Jr.) + the $2.2B opportunity
- 10:00 Why this is a win. Safety through legitimacy, licensed compounding pharmacies
- 13:50 What this means if you're already using peptides
- 17:30 BPC-157. The recovery superstar. Doses, cycles, uses
- 20:35 TB-500. The recovery partner. The Wolverine stack with BPC-157
- 22:00 KPV. The anti-inflammatory gem for gut and skin
- 23:10 MOTS-c. Exercise mimetic, metabolic and mitochondrial support
- 25:35 Today's vote. DSIP for sleep, Epitalon for longevity, Semax for focus
- 27:15 Free base vs acetate explained
- 28:20 What this means for women
- 30:40 The future. Nothing is fully legal yet. The FDA still gets the final vote
- 34:15 If you don't have a doctor. How the US telehealth model will work
- 35:05 What this means for Canadians + global listeners
- 36:45 Peptides are here to stay. The cultural moment already happened
Resources:
My free, trusted Peptide Source Guide. My vetted global peptide companies.
Work with me one-on-one.
The Her Stack Planner (digital, physical coming soon).
Join The LongHer Life Longevity Community.
Let's connect:
- Instagram, TikTok, Facebook
- Shop my favorite health products
- Listen on Spotify, Apple Podcasts, YouTube Music